11/13/2009

Bayer plans to increase spending next year on research and development, which is valued at about $4.3 billion, CEO Werner Wenning said. The company announced in September that it will invest more than $100 million at its plant in Berkeley, Calif., to produce hemophilia drug Kogenate.

Related Summaries